July 2023 - Cytopathology and Pulmonary Pathology - Insights
This "Pathways" program provides an Anatomic Pathology case that includes a history, potential answers, rationale, and relevant references. This case sub-specialty is Cytopathology & Pulmonary Pathology.
June 2023 - Gynecologic Pathology - Insights
This "Pathways" program provides an Anatomic Pathology case that includes a history, potential answers, rationale, and relevant references. This case sub-specialty is Gynecological Pathology.
Mayo Clinic Laboratory and Pathology Research Roundup: Dec. 4 - Insights
This week’s Research Roundup highlights extensive virologic and immunologic characterization in an HIV-infected individual following allogeneic stem cell transplant and analytic cessation of antiretroviral therapy.
Membranous nephropathy - Insights
Membranous nephropathy (MN) is one of the leading causes of nephrotic syndrome in adults. Our menu of clinically validated assays assists with diagnosis, monitors disease progression, and guides clinical outcomes.
Chromosomal microarray better informs brain tumor diagnosis - Insights
Molecular biomarkers are a critical component in the treatment of adult and pediatric brain tumors. Robert Jenkins, M.D., Ph.D., explains how Mayo Clinic Laboratories' chromosomal microarray provides more comprehensive and accurate tumor...
Multiple Sclerosis Profile Updates - Insights
Maria Alice Willrich, Ph.D., explains kappa free light chain testing — Mayo Clinic Laboratories' data-driven approach to diagnose multiple sclerosis. The automated assay is more sensitive, cost-effective, and faster than traditional...
Paraneoplastic Vision Loss Evaluation [Test in Focus] - Insights
Andrew McKeon, M,B., B.Ch., M.D., provides an overview of Mayo Clinic Laboratories' new paraneoplastic vision loss evaluation — a test that can help direct a cancer diagnosis and guide treatment. He reviews why this test was developed, when...
Find out more about UBA1Q, a quantitative droplet digital polymerase chain reaction (ddPCR) assay that targets seven possible mutations that can occur in the UBA1 gene and help identify VEXAS syndrome.
TPNUQ genotyping assay - Insights
Ann Moyer, M.D., Ph.D., discusses TPNUQ, Mayo Clinic Laboratories' genotyping test for identifying patients at risk for thiopurine toxicity. Used prior to therapy initiation, our assay evaluates for nuances in both TPMT and NUDT15, which...
Colorectal panel provides detailed cancer information - Insights
Rondell Graham, M.B.B.S., describes Mayo Clinic Laboratories' new colorectal cancer panel. The assay covers more genes to better inform decision-making about prognosis, targeted therapies and a hereditary cancer syndrome.